Table 1.

Characteristics of the subjects at baseline, at transition and 12 weeks after the transition

Variable	Baseline (12 week before transition)	At transition	12 weeks after transition
HbA1c (%)	8.02 ± 0.60	8.08 ± 0.57	7.45 ± 0.38†*
Fasting BG (mmol/L)	4.78 ± 0.60	4.64 ± 0.66	6.25 ± 0.31†*
Postprandial BG (mmol/L)	6.76 ± 0.80	6.65 ± 0.75	6.56 ± 0.57
Pre-lunch BG (mmol/L)	7.41 ± 0.80	7.40 ± 0.81	6.81 ± 0.46†*
Pre-dinner BG (mmol/L)	10.31 ± 1.20	9.84 ± 0.74	6.87 ± 0.38†*
BMI (g/cm2)	23.54 ± 3.18	23.54 ± 3.18	23.52 ± 2.46
Body weight (kg)	70.33 ± 15.21	70.33 ± 15.21	70.10 ± 13.93
Total cholesterol (mmol/L)	4.5 ± 0.40	4.37 ± 0.52	4.30 ± 0.47
Triglycerides (mmol/L)	2.1 ± 0.60	1.93 ± 0.50*	1.72 ± 0.37†*
HDL (mmol/L)	1.01 ± 0.09	1.07 ± 0.17	1.20 ± 0.10†*
LDL (mmol/L)	3.30 ± 0.40	3.14 ± 0.44	3.07 ± 0.44
Daily dose of basal insulin (IU)	24.60 ± 6.60	23.35 ± 5.90	24.24 ± 6.96
Proportion of patients experienced morning hypoglycemia (n/%)	18/100.0	18/100.0	11/61.0II
Proportion of patients experienced nocturnal hypoglycemia (n/%)	12/66.6	13/72.2	5/27.7II
Average number of morning hypoglycemias per month per patient	4.30 ± 1.60	3.66 ± 1.40‡	0.63 ± 0.74§‡
Average number of nocturnal hypoglycemias per month per patient	0.70 ± 0.60	0.69 ± 0.51	0.22 ± 0.39§‡
Total number of morning hypoglycemias	78	66	12*†
Total number of nocturnal hypoglycemias	13	13	4*†

HbA1c glycated hemoglobin, BG blood glucose, BMI body mass index, HDL high-density lipoprotein, LDL low-density lipoprotein, IU international unit

Paired Student’s t test; * p < 0.01 vs. baseline; ^† p < 0.01 vs. transition; Wilcoxon Signed Ranks Test; ^‡ p < 0.01 vs. baseline; ^§ p < 0.01 vs. transition; Fisher exact test; ^II p < 0.01 vs. transition